Clinical Trial Detail

NCT ID NCT03650348
Title PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pieris Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Atezolizumab + PRS-343

Age Groups: adult senior

Additional content available in CKB BOOST